NasdaqGS - Nasdaq Real Time Price USD

Puma Biotechnology, Inc. (PBYI)

3.0400

+0.0600

+(2.01%)

At close: April 29 at 4:00:00 PM EDT

3.0400

0.00

(0.00%)

After hours: April 29 at 4:17:30 PM EDT

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

LOS ANGELES, April 28, 2025--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.

Business Wire yesterday

PBYI
+2.01%
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

LOS ANGELES, April 24, 2025--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.

Business Wire 5 days ago

PBYI
+2.01%
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 6 days ago

PBYI
+2.01%
Is the Options Market Predicting a Spike in Puma Biotechnology Stock?

Investors need to pay close attention to PBYI stock based on the movements in the options market lately.

Zacks 8 days ago

PBYI
+2.01%
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, April 02, 2025--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

Business Wire 27 days ago

PBYI
+2.01%
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

It is hard to get excited after looking at Puma Biotechnology's (NASDAQ:PBYI) recent performance, when its stock has...

Simply Wall St. last month

PBYI
+2.01%
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

LOS ANGELES, March 26, 2025--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.

Business Wire last month

PBYI
+2.01%
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Zacks last month

PBYI
+2.01%
Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Puma Biotechnology, Inc. (NASDAQ:PBYI) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting lows, and the energized chase after the next big opportunity […]

Insider Monkey last month

PBYI
+2.01%
We Think Puma Biotechnology's (NASDAQ:PBYI) Healthy Earnings Might Be Conservative

Investors signalled that they were pleased with Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) most recent earnings report...

Simply Wall St. last month

PBYI
+2.01%
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

LOS ANGELES, March 05, 2025--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach.

Business Wire last month

PBYI
+2.01%
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

PBYI
+2.01%
Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

As you might know, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) just kicked off its latest annual results with some very...

Simply Wall St. last month

PBYI
+2.01%
Q4 2024 Puma Biotechnology Inc Earnings Call

Q4 2024 Puma Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents last month

PBYI
+2.01%
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.

Zacks last month

PBYI
+2.01%
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks

The U.S. stock market has recently experienced volatility, with tech stocks leading a significant sell-off amid concerns about economic policies and tariffs. In such uncertain times, investors often seek opportunities in less conventional areas of the market. Penny stocks, while an older term, still capture the imagination by offering potential growth at lower price points. These smaller or newer companies can present valuable opportunities when backed by solid financials and fundamentals.

Simply Wall St. last month

GDRX

PBYI
+2.01%
XNET
Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Puma Biotechnology Inc (PBYI) reports strong revenue growth and strategic distribution expansions, despite facing challenges in royalty revenue and new patient acquisition.

GuruFocus.com last month

PBYI
+2.01%
Puma Biotech: Q4 Earnings Snapshot

LOS ANGELES (AP) — Puma Biotechnology Inc. PBYI) on Thursday reported fourth-quarter profit of $19.3 million. On a per-share basis, the Los Angeles-based company said it had net income of 39 cents.

Associated Press Finance last month

PBYI
+2.01%
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

LOS ANGELES, February 27, 2025--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.

Business Wire last month

PBYI
+2.01%
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference

LOS ANGELES, February 26, 2025--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marriott Copley Place in Boston.

Business Wire 2 months ago

PBYI
+2.01%

Performance Overview

Return	PBYI	S&P 500 (^GSPC)
YTD	-0.33%	-5.45%
1-Year	-39.44%	+8.69%
3-Year	+28.81%	+34.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

Is the Options Market Predicting a Spike in Puma Biotechnology Stock?

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why

Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now

We Think Puma Biotechnology's (NASDAQ:PBYI) Healthy Earnings Might Be Conservative

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Q4 2024 Puma Biotechnology Inc Earnings Call

PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks

Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Puma Biotech: Q4 Earnings Snapshot

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference

Performance Overview